|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.64 CNY | +2.01% |
|
-0.21% | -38.99% |
| 05-16 | Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials | MT |
| 04-25 | Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Chengdu Olymvax Biopharmaceuticals Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was CNY 547.48 million compared to CNY 487.15 million a year ago. Net income was CNY 26.57 million compared to CNY 107.96 million a year ago.
Basic earnings per share from continuing operations was CNY 0.0656 compared to CNY 0.2804 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -38.99% | 539M | |
| +2.97% | 94.74B | |
| -4.08% | 37.28B | |
| -13.26% | 32.68B | |
| +74.52% | 27.72B | |
| -11.58% | 16.19B | |
| -1.66% | 13.88B | |
| -11.67% | 11.58B | |
| +190.36% | 10.92B | |
| -52.61% | 9.54B |
CHENGDU OLYMVAX BIOPHARMACEUTICALS INC. 
